Halozyme CEO Helen Torley disposes of 1,923 common shares worth $146,852.55

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

HALO

0.00
  • Halozyme CEO Helen Torley exercised options for 1,923 shares at $12.07 on July 8, 2026, lifting direct holdings to 769,703 shares.
  • Torley sold 1,923 shares the same day at weighted average prices of $79.28 and $80.19, cutting direct holdings to 767,780 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000100), on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.